AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18089634
Drug: Pamidronate 6
RxNorm normalized name: pamidronate 6 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 6 mg/kg/year
Trial: 18089634
Drug: Pamidronate (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (both doses)
Trial: 16968913
Drug: Primaquine phosphate
RxNorm normalized name: Primaquine Phosphate
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine phosphate (30 mg base daily for 14 days for PART; 30 mg daily for primary prophylaxis)
Trial: 9352971
Drug: Intravenous conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous conjugated estrogens (0.625 mg)
Trial: 28730396
Drug: FRIENDS for
RxNorm normalized name: Aluminum Zirconium Tetrachlorohydrex GLY 17.8 g in 100 g TOPICAL STICK [DEGREE GIRL FRIENDS FOREVER ANTIPERSPIRANT AND DEODORANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRIENDS for Life intervention administered by trained teachers
Trial: 26360125
Drug: Once-daily extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily extended-release tacrolimus
Trial: 24678064
Drug: Topical cocaine
RxNorm normalized name: cocaine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cocaine
Trial: 24678064
Drug: Topical adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical adrenaline
Trial: 21308791
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and ezetimibe on top of oral anticoagulation therapy
Trial: 20519663
Drug: Metformin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (n = 125, IDPP-1)
Trial: 20519663
Drug: LSM +
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LSM + Metformin (n = 121, IDPP-1)
Trial: 18509244
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 administration for 6 months
Trial: 3168077
Drug: alpha‐2b interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐2b interferon treatment (5 IU three times weekly by subcutaneous injection for 16 weeks)
Trial: 3168077
Drug: alpha‐2b interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐2b interferon treatment
Trial: 29871264
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray combined with montelukast (MOM+M)
Trial: 29871264
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray combined with loratadine (MOM+L)
Trial: 29871264
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray (MOM)
Trial: 21466700
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (simple end-to-end repair of the tendon with no augmentation)
Trial: 18050368
Drug: Etidronate disodium
RxNorm normalized name: Etidronate Disodium
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate disodium (200 mg per day for 2 weeks) with 3.0 g of calcium lactate and 0.75 microg of alphacalcidol daily
Trial: 10852452
Drug: Raloxifene (Evista,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (Evista, 60 mg/day)
Trial: 10852452
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE; Premarin, 0.625 mg/day)
Trial: 8096389
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate patches releasing 15 mg/24 h
Trial: 27386644
Drug: Zaozhu Yinchen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaozhu Yinchen Recipe (ZZYCR), one dose per day for 24 weeks
Trial: 27386644
Drug: Silibin Meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silibin Meglumine Tablets, 20 mg thrice per day for 24 weeks
Trial: 12821739
Drug: High-dose cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cooling therapy for 1 hour
Trial: 12821739
Drug: Low-dose cooling
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cooling therapy for 1 hour
Trial: 12821739
Drug: Daily cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cooling garment use for 1 hour each day for a month
Trial: 10834668
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at a target plasma concentration of 100 ng/mL
Trial: 10834668
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at a target plasma concentration of 200 ng/mL
Trial: 31437195
Drug: Blood loss
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood loss 500-999 ml
Trial: 15934285
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy and IFN‐gamma treatment (1000000 IU im qod)
Trial: 15934285
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (control group)
Trial: 12468782
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg/d for 2 to 8 weeks
Trial: 9785786
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with propofol (1 mg.kg‐1 bolus followed by 4 mg.kg‐1.h‐1 continuous infusion)
Trial: 9785786
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with propofol (1 mg.kg‐1 bolus followed by 4 mg.kg‐1.h‐1 continuous infusion)
Trial: 7894881
Drug: Antidepressant alone
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant alone (placebo)
Trial: 327623
Drug: Primary radiation
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary radiation therapy for stage I cases without randomization, followed or not by maintenance chemotherapy.
Trial: 327623
Drug: Mantle field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mantle field therapy for supradiaphragmatic stage II, followed if necessary by prophylactic infradiaphragmatic irradiation.
Trial: 327623
Drug: Two regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two regimens of maintenance chemotherapy for all stages II, randomized.
Trial: 327623
Drug: Two regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two regimens of induction chemotherapy for stages III and IV, followed by maintenance chemotherapy.
Trial: 31553134
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan (AZL) 20 mg single dose
Trial: 31553134
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan (AZL) 40 mg single dose
Trial: 31553134
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan (AZL) 40 mg/d for 7 days (multiple doses)
Trial: 31553134
Drug: Azilsartan (AZL)
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan (AZL) 40 mg single dose under fasted and fed conditions
Trial: 31696504
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (42 patients, 10M/32F, mean age 32.23 ± 10.3 years) treated with ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for one week, supplemented with probiotic mix (1 sachet twice a day for 10 days)
Trial: 31696504
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (42 patients, 15M/27F, mean age 59.01 ± 11.3 years) received the same antibiotic treatment without the probiotic mix
Trial: 24235233
Drug: Chlorine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorine (200 mg/kg)
Trial: 21470834
Drug: Higher prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher prescribed dose
Trial: 14660997
Drug: HMG CoA
RxNorm normalized name: HMG CoA reductase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG CoA reductase inhibitors
Trial: 8989069
Drug: Fluconazole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (3 mg/kg daily orally) and placebo (100 mg/kg/daily orally)
Trial: 8989069
Drug: Itraconazole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (3 mg/kg daily orally) and flucytosine (100 mg/kg daily orally)
Trial: 8989069
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 mg/kg daily orally) and placebo (100 mg/kg daily orally)
Trial: 1453306
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ibuprofen immediately presurgically
Trial: 1453306
Drug: Placebo before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before surgery and 600 mg ibuprofen postsurgically
Trial: 2981982
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin and vindesine (PVD)
Trial: 23926117
Drug: Ezetimibe/Simvastatin (E/S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Simvastatin (E/S) + Niacin (N) (10/20 mg/day + titrated to 2 g/day)
Trial: 23926117
Drug: Niacin (N)
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin (N) (titrated to 2 g/day)
Trial: 23926117
Drug: Ezetimibe/Simvastatin (E/S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Simvastatin (E/S) (10/20 mg/day)
Trial: 21874559
Drug: bilastine 50
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: bilastine 50 mg
Trial: 21874559
Drug: bilastine 20
RxNorm normalized name: Bilastine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bilastine 20 mg
Trial: 19903187
Drug: Multiple-dose LRPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose LRPT 40 mg/day for 7 days coadministered with single-dose rosiglitazone 4 mg
Trial: 19903187
Drug: Single-dose rosiglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose rosiglitazone 4 mg
Trial: 17257457
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac epolamine plaster (DHEP)
Trial: 12939586
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment (various methods including vasoactive drugs, endoscopic therapy, combined therapy, balloon tamponade)
Trial: 11466698
Drug: BCNU (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCNU (150 mg/m(2) on Day 3) plus IFN‐alpha (12 million U/m(2) on Days 1‐3, Weeks 1, 3, and 5) every 7 weeks for a maximum of 6 cycles
Trial: 11466698
Drug: BCNU alone
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCNU alone (200 mg/m(2) on Day 1)
Trial: 28326881
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10^9 CFU/g each) for six weeks
Trial: 9085960
Drug: Morphine (0.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.75, 1.0, or 1.5 mg bolus dose size)
Trial: 9085960
Drug: Meperidine (9,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (9, 12, or 18 mg)
Trial: 9085960
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and Meperidine
Trial: 8448101
Drug: Articaine 4%
RxNorm normalized name: ARTICAINE 4%/EPI 1:200000 INJ CART 1.7ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine 4% with 20 micrograms epinephrine (2 mL)
Trial: 2891754
Drug: Metronidazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (500 mg intravenous intra-operative dose)
Trial: 27815079
Drug: AnisEncap (enteric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AnisEncap (enteric coated capsules of anise oil)
Trial: 23270200
Drug: no foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no foam (blank patch)
Trial: 356252
Drug: Inhaled RS
RxNorm normalized name: (RS)-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled RS 7540 (40 mg)
Trial: 356252
Drug: Inhaled RS
RxNorm normalized name: (RS)-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled RS 7540 (20 mg)
Trial: 27217047
Drug: Tacrolimus with
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus with azole antifungal agents (AZ)
Trial: 27217047
Drug: Tacrolimus without
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus without azole antifungal agents (AZ)
Trial: 22250191
Drug: Selective BRAF
RxNorm normalized name: Braftovi
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Selective BRAF inhibitors
Trial: 22250191
Drug: Analgesic and
RxNorm normalized name: otologic analgesic and anesthetic combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic and anti-inflammatory treatment (e.g., etoricoxib)
Trial: 22250191
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction of BRAF inhibitor
Trial: 17645554
Drug: Sulphonylurea treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphonylurea treatment in addition to dietary regulation and increased exercise
Trial: 15955935
Drug: Gabapentin (GBP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP) 1,500 mg/day
Trial: 15955935
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) 150 mg/day
Trial: 11839708
Drug: Adrenaline injection
RxNorm normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenaline injection plus heater probe thermocoagulation
Trial: 10405498
Drug: Adderall (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall (single dose)
Trial: 10405498
Drug: Methylphenidate (2
RxNorm normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (2 daily doses)
Trial: 7749423
Drug: High-CHO diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-CHO diet of 10.52 +/‐ 0.57 g/kg body mass/day
Trial: 7749423
Drug: Normal CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal CHO intake of 6.15 +/‐ 0.23 g/kg body mass/day
Trial: 2309227
Drug: Intrapleural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural bupivacaine (20 ml of 0.25% bupivacaine for 48 hours)
Trial: 398485
Drug: Ampicillin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (50 mg/kg/day in 4 divided doses for 5 days)
Trial: 398485
Drug: Cefaclor (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (50 mg/kg/day in 3 divided doses for 5 days)
Trial: 31808786
Drug: Informational treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Informational treatment about opioids
Trial: 30714749
Drug: Group interpersonal
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group interpersonal psychotherapy (IPT) plus treatment as usual (TAU)
Trial: 28345762
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate diet (LCD) (≤50 g/d)
Trial: 28345762
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate diet (HCD) (≥250 g/d)
Trial: 24151390
Drug: Anisodamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anisodamine (10 mg every 8 hours for 2 weeks)
Trial: 17243700
Drug: Tangerine sauce
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangerine sauce (150 g containing 15 g of corn oil, 13 mg of lycopene)
Trial: 17243700
Drug: High-beta-carotene sauce
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-beta-carotene sauce (150 g containing 15 g of corn oil, 17 mg of total beta-carotene, 4 mg of lycopene)
Trial: 14722172
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 2 micro g kg(‐1)
Trial: 14722172
Drug: Caudal clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caudal clonidine 2 micro g kg(‐1)
Trial: 3287973
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefotetan as a single prophylactic dose
Trial: 3287973
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefotetan as a single dose
Trial: 3287973
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefoxitin every 6 hours for a maximum of 4 doses
Trial: 24244339
Drug: Ad35.CS.01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad35.CS.01 vaccine (10^9, 10^10, 5X10^10, 10^11 vp) administered on days 0, 28, and 84
Trial: 24244339
Drug: Ad35.CS.01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad35.CS.01 vaccine
Trial: 14748475
Drug: Cyclical etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical etidronate treatment (200 mg/day for 2 weeks per 3 months)
Trial: 14748475
Drug: Alendronate treatment
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate treatment (5 mg/day)
Trial: 8642881
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment using a bilevel positive airway pressure (PAP) device set to deliver an inspiratory pressure of 0 cm H2O and a minimal expiratory pressure of 2 cm H2O.
Trial: 8642881
Drug: Nocturnal nasal
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nocturnal nasal ventilation (NNV) and Sham treatment
Trial: 1505287
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg at night (2200 hr)
Trial: 1505287
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg three times a day (1800, 0800 and 1200 hr)
Trial: 6098223
Drug: Hand lotion
RxNorm normalized name: CVS Intense Dry Skin Therapy Hand Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand lotion containing 2% glutaric acid
Trial: 9822501
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 as a 0.5-mg intracervical gel (Prepidil) with immediate oxytocin
Trial: 9822501
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 as a 10-mg controlled-release vaginal insert (Cervidil) with delayed oxytocin
Trial: 7927956
Drug: Ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5 mg plus Hydrochlorothiazide 12.5 mg
Trial: 2913132
Drug: Albuterol repeat‐action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol repeat‐action tablets with a high fat content breakfast
Trial: 2913132
Drug: Albuterol repeat‐action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol repeat‐action tablets without food
Trial: 163848
Drug: Polymyxin aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin aerosol (2.5 mg/kg body wt/day in six divided doses)
Trial: 28537001
Drug: tiotropium/olodaterol fixed‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium/olodaterol fixed‐dose combination (FDC)
Trial: 27503566
Drug: TRPV1 agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRPV1 agonist (capsaicin 1 × 10(−5) M)
Trial: 25171815
Drug: Carbohydrate/Electrolyte Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate/Electrolyte Solution (CES)
Trial: 17150023
Drug: ID-KLH vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID-KLH vaccine plus granulocyte-macrophage colony-stimulating factor